| Formulation |
Brand Names |
Duration |
Dosing |
Approval |
| Immediate-release tablet |
Zenzedi |
4–5 hours |
2nd dose at lunch |
Ages 3 to 16 |
| Immediate-release oral solution |
ProCentra (previously Liquadd) |
4–6 hours |
2nd dose at lunch |
Ages 3 to 16 |
| Extended-release capsule |
Dexedrine |
6–8 hours |
Once-daily in the morning |
Ages 6 to 16 |
| Transdermal system |
Xelstrym |
Peak at 6 hours |
Once-daily in the morning, 2 hours before effect is needed |
Ages 6 and older |
| Lisdexamfetamine dimesylate capsule |
Vyvanse |
Up to 12 hours, peak at 3.5 hours |
Once-daily in the morning |
Ages 6 and older |
| |
| Amphetamine (d, l) Formulations |
| Formulation |
Brand Names |
Duration |
Dosing |
Approval |
| Immediate-release tablet |
Adderall |
4-6 hours |
2nd dose at lunch |
Ages 3 and older |
| Immediate-release tablet |
Evekeo |
6 hours |
2nd dose at lunch |
Ages 3 and older |
| Orally disintegrating tablet |
Evekeo ODT |
6 hours |
2nd dose at lunch |
Ages 3 to 17 |
| Extended-release tablet |
Adderall XR |
8-12 hours, peak at 6–8 hours |
Once-daily in the morning |
Ages 6 and older |
| Extended-release orally disintegrating tablets |
Adzenys XR-ODT |
8-12 hours, peak at 5 hours |
Once-daily in the morning |
Ages 6 and older |
| Extended-release oral suspension |
Dyanavel XR |
10-12 hours, peak at 4 hours |
Once-daily in the morning |
Ages 6 to 17 |
| Extended-release tablet |
Dyanavel XR |
10-12 hours, peak at 4 hours |
Once-daily in the morning |
Ages 6 to 17 |
| Extended-release capsule |
Mydayis |
Up to 16 hours |
Once-daily in the morning |
Ages 13 and older |